A at a glance
Agilent Technologies (A, SEC CIK 1090872) filed its latest 10-K annual report on December 22, 2025, a 10-Q quarterly report on September 1, 2026, an 8-K current report on November 20, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended October 31, 2025 (FY2025), Agilent Technologies (A) reported revenue of $6.9 billion (up 6.7% from FY2024) and net income of $1.3 billion. Diluted EPS was $4.57.
- As of September 30, 2026, 44 institutional investment managers tracked by SignalX reported holding Agilent Technologies (A) shares worth $19.7 billion in 13F-HR filings.
- In the last 90 days, A insiders reported 0 open-market purchases ($0) and 1 open-market sale ($96K) on Form 4, a net sale of $96K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $6.9B
- +6.7% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$96K
- 13F holders
- 44 funds
- $19.7B · +2 vs prior quarter
- Latest 8-K
- Nov 20, 2026
- Item 5.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Oct 31, 2025
Risk Factors
- Regulatory risk from Inflation Reduction Act 2022, 1% nondeductible excise tax on stock repurchases payable, $3 million recorded in fiscal 2025
- Geopolitical risk from U.S. tariff changes in H2 2025 increasing cost of revenue; mitigation expected in fiscal 2026 through supply chain and pricing actions
- Operational risk in inventory valuation: potential write-downs if actual market conditions worsen beyond management's estimates on excess and obsolete inventory
- Competitive risk from capital spending declines in pharmaceutical market affecting Life Sciences and Diagnostics segment revenue growth, down 11% in 2024 vs 2023
- Financial risk from goodwill and intangible asset impairment assessment, relying on significant estimates including revenue growth and discount rates, with no impairment recognized in 2025
Business Overview
- Core business model: Provider of scientific instruments and analytical solutions for laboratories and research
- No new products, services, or business segments introduced or emphasized in this year's filing
- Continued focus on equity compensation plans, including 2018 Stock Plan with 38.8 million shares available for future issuance
- Notable metric: 2,954,318 securities outstanding under equity compensation plans with weighted-average exercise price $134
- Most unusual detail: Annual increase mechanism in Employee Stock Purchase Plan allows up to 1% of outstanding shares for future issuance
Management Discussion & Analysis
- Revenue and profitability figures not disclosed in provided MD&A text
- No cash flow, buybacks, dividends, or capex details mentioned
- Forward-looking statements highlight growth opportunities, investments, market demand, and macroeconomic risks without specific guidance or figures
AI summary of the A 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jul 31, 2026
Management Discussion & Analysis
- Revenue $1,878M, up 8% YoY from $1,738M
- Operating margin 23.6% vs 20.7% YoY; gross margin 55.5% vs 51.1%
- Best segment Life Sciences and Diagnostics Markets: $746M, up 11% YoY
- Operating cash flow $1,064M vs $1,014M; $78M share repurchases and $72M dividends
- Outlook: normalized customer capital budgets; tariff and Middle East risks remain dynamic
Risk Factors
- No explicit newly added risk identified; filing continues previously disclosed business, regulatory, and financial risks
- International exposure: foreign-exchange movements favorably affected revenue growth by 2 percentage points in nine months ended July 31, 2026
- Privacy compliance: GDPR violations can trigger fines of up to 4% of total company revenue
- Trade and geopolitical disruption: tariffs, sanctions, and export controls may restrict shipments and critical-component sourcing
- Demand volatility: customer orders remain difficult to forecast and may be delayed or cancelled during market declines
AI summary of the A 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- George A. Scangos retiring from Agilent’s Board effective December 1, 2026
- Departure unrelated to disagreements over operations, policies or practices
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Chairperson Boon Hwee Koh retiring September 4, 2026 after 23 years, with no operational or policy disagreements
- Glenn Boehnlein appointed Class III director effective September 4, 2026, standing for re-election at the 2027 annual meeting
Item EX-99.1: Item EX-99.1
- Board chair Koh Boon Hwee retired September 4 after more than 20 years, ending long-standing governance continuity
- Dow R. Wilson became chair, supporting leadership continuity with company knowledge and prior Audit and Finance Committee experience
Item 7.01: Regulation FD Disclosure
- Board leadership transition: Mr. Koh retiring from Agilent’s Board
- Mr. Boehnlein appointed as a new director
Item 2.02: Results of Operations and Financial Condition
- Agilent reported fiscal Q3 2026 results for the quarter ended July 31, 2026
- Press release Exhibit 99.1 contains the financial results and management commentary
Item EX-99.1: Item EX-99.1
- Q3 revenue $1.88B, up 8.1% reported and 7.3% core, signaling broad-based demand recovery
- GAAP operating margin 23.6%, up 290 basis points, while non-GAAP margin reached 28.3%
AI summaries of A 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for A
Don't miss the next A filing
- Alerts as it files. A push when A files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut A, by share count.
- Ask anything. An AI agent that reads every A filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Henson Meghan | F | Nov 18, 2026 | 467 | $177.33 |
| ZHANG JIANMIAO MIKE | F | Nov 18, 2026 | 454 | $177.33 |
| Elinoff Adam Stewart | F | Nov 18, 2026 | 1,019 | $177.33 |
| MAY SIMON | F | Nov 18, 2026 | 844 | $177.33 |
| RIEMANN ANGELICA | F | Nov 18, 2026 | 844 | $177.33 |
| MCDONNELL PADRAIG | F | Nov 18, 2026 | 4,147 | $177.33 |
| KIRKWOOD JONAH PREVOST | F | Nov 18, 2026 | 813 | $177.33 |
| RIEMANN ANGELICA | F | Nov 17, 2026 | 2,213 | $172.22 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $6.5B | $6.9B |
| Operating Income | - | $1.5B | $1.5B |
| Net Income | $1.2B | $1.3B | $1.3B |
| Op. Margin | - | 22.9% | 21.3% |
| Net Margin | - | 19.8% | 18.8% |
| Balance Sheet | |||
| Total Assets | $10.8B | $11.8B | $12.7B |
| Equity | - | $5.9B | $6.7B |
| ROE | - | 21.9% | 19.3% |
| Per Share | |||
| EPS | $4.19 | $4.43 | $4.57 |
| Cash Flow | |||
| Operating CF | - | $1.8B | $1.6B |
| CapEx | $298.0M | $378.0M | $407.0M |
Source: XBRL data in Agilent Technologies (A)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate A share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 44 | $19.66B |
| Q2 2026 | 42 | $15.43B |
| Q1 2026 | 43 | $12.40B |
| Q4 2025 | 41 | $14.29B |
| Q3 2025 | 42 | $13.65B |
| Q2 2025 | 40 | $12.31B |
| Q1 2025 | 39 | $8.97B |
| Q4 2024 | 34 | $8.80B |
- BNY Mellon+1.80M (+34%)
- AQR Capital Management+837.1K (+23%)
- BlackRock+512.2K (+2%)
- Prudential Financial+355.1K (+228%)
- Bridgewater Associates LP+332.7K (+1454%)
- Goldman Sachs Group−868.8K (-18%)
- D.E. Shaw & Co−865.6K (-58%)
- Franklin Resources−792.3K (-65%)
- Citadel Advisors LLC−564.1K (-51%)
- Morgan Stanley−146.5K (-3%)
- FMR LLC (Fidelity)−5.08M
- Two Sigma Investments−23.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 325 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
A filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 20, 2026 | - | Analysis | - |
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 10-Q | Sep 1, 2026 | Jul 31, 2026 | Analysis | |
| 8-K | Aug 26, 2026 | - | Analysis | - |
| 4 | Jun 29, 2026 | - | - | - |
| 8-K | Jun 25, 2026 | - | Analysis | - |
| 4 | Jun 5, 2026 | - | - | |
| 10-Q | Jun 1, 2026 | Apr 30, 2026 | Analysis | |
| 8-K | May 27, 2026 | - | Analysis | |
| 4 | May 12, 2026 | - | - | |
| 8-K | May 4, 2026 | - | Analysis | - |
| SC 13G | Apr 29, 2026 | - | - |
Related Health Care companies
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- ALMR · Alamar Biosciences IncLaboratory Analytical Instruments
- AVTR · Avantor IncLaboratory Analytical Instruments
- BIO · Bio-rad Laboratories IncLaboratory Analytical Instruments
- BRKR · Bruker CorpLaboratory Analytical Instruments
- CTKB · Cytek Biosciences, Inc.Laboratory Analytical Instruments
- EYPT · EyePoint, Inc.Laboratory Analytical Instruments
- ILMN · Illumina IncLaboratory Analytical Instruments
A SEC filings: frequently asked questions
Are A insiders buying or selling?
In the last 90 days, Agilent Technologies (A) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $95,972 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold A stock?
As of September 30, 2026, the largest Agilent Technologies (A) holders among the 13F filers tracked by SignalX were BlackRock ($4.5 billion), Vanguard Capital Management LLC ($3.2 billion), Vanguard Portfolio Management LLC ($2.5 billion), State Street Corp ($2.2 billion), BNY Mellon ($1.2 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was A's revenue in fiscal year 2025?
For the fiscal year ended October 31, 2025 (FY2025), Agilent Technologies (A) reported revenue of $6.9 billion (up 6.7% from FY2024) and net income of $1.3 billion. Diluted EPS was $4.57. The figures come from the XBRL data in the 10-K.
What are the main risks in A's latest 10-K?
In the 10-K filed December 22, 2025, Agilent Technologies (A) flagged: Regulatory risk from Inflation Reduction Act 2022, 1% nondeductible excise tax on stock repurchases payable, $3 million recorded in fiscal 2025. Geopolitical risk from U.S. tariff changes in H2 2025 increasing cost of revenue; mitigation expected in fiscal 2026 through supply chain and pricing actions. (AI summary of the Risk Factors section.)
What did A report in its latest 8-K?
Agilent Technologies (A) filed an 8-K on November 20, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). George A. Scangos retiring from Agilent’s Board effective December 1, 2026.
What are the latest A SEC filings?
Agilent Technologies (A) filed its latest 10-K annual report on December 22, 2025, a 10-Q quarterly report on September 1, 2026, an 8-K current report on November 20, 2026 and a Form 4 insider filing on November 19, 2026.
What is A's SEC CIK number?
Agilent Technologies (A)'s SEC Central Index Key (CIK) is 1090872. EDGAR lists every A filing under that number.
Ask anything about A
The research agent reads A's filings, financials, insider trades and 13F holders, then answers with sources.